<DOC>
	<DOCNO>NCT00001705</DOCNO>
	<brief_summary>Patients metastatic melanoma HLA-A201+ immunize modify peptide gp100 molecule contain signal sequence design improve peptide presentation antigen present cell . This peptide call gp100 : ES209-217 ( 210M ) administer either alone combination high low dose IL-2 . Patients evaluate clinical response , well undergo study immunologic response peptide immunization .</brief_summary>
	<brief_title>Immunization Patients With Metastatic Melanoma Using GP100 Peptide Preceded Endoplasmic Reticulum Insertion Signal Sequence</brief_title>
	<detailed_description>Patients metastatic melanoma HLA-A201+ immunize modify peptide gp100 molecule contain signal sequence design improve peptide presentation antigen present cell . This peptide call gp100 : ES209-217 ( 210M ) administer either alone combination high low dose IL-2 . Patients evaluate clinical response , well undergo study immunologic response peptide immunization .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Any patient age great equal 18 measurable metastatic melanoma fail standard treatment expect survival great three month consider . Serum creatinine 2.0 mg/dl less . Bilirubin 1.6 mg/dl less . WBC 3000/mm ( 3 ) great . Platelet count 90,000 mm ( 3 ) great . Serum AST/ALT less two time normal . ECOG performance status 0 1 2 . Patients gender must willing practice effective birth control trial . No patient undergo undergone past 3 week form therapy except surgery cancer . No patient active systemic infection , coagulation disorder , autoimmune disease major medical illness cardiovascular respiratory system know immunodeficiency disease . Patients cardiovascular disease eligible receive peptide IFA alone . No patient require steroid therapy . No patient pregnant ( possible side effect fetus ) . No patient know positive hepatitis BsAG HIV antibody ( possible immune effect condition ) . No patient form primary secondary immunodeficiency . ( The experimental treatment evaluate protocol depends intact immune system . Patients decrease immune competence may less responsive experimental treatment susceptible toxicity ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>Antigen</keyword>
	<keyword>Cancer</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>